Orthocell's September Quarter Revenue Meets Fiscal 2026 Expectations, Euroz Hartleys Says

MT Newswires Live

10/03

Orthocell's (ASX:OCC) record revenue of AU$3 million for the September quarter, up 9.1% quarter over quarter, is consistent with Euroz Hartleys' fiscal 2026 revenue estimate of AU$14.4 million, according to a Thursday note from the investment advisory firm.

The first-quarter growth was due to higher sales of Remplir, the company's nerve repair product, in Australia and Singapore, Euroz Hartleys said.

Though Remplir did not have a material revenue contribution from the US market, Euroz Hartleys noted that the company expects US sales to start ramping up from the December quarter.

"The US rollout of Remplir remains central to our investment thesis," the investment advisory firm added.

Euroz Hartleys maintained Orthocell's hold rating and raised its price target to AU$1.36 from AU$1.30.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2572631522"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2572631522\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2572631522?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-03 08:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2572631522","market":"us","top_or_hot":-1,"title":"Orthocell's September Quarter Revenue Meets Fiscal 2026 Expectations, Euroz Hartleys Says","media":"MT Newswires Live","content":"<html><body><p> Orthocell's (ASX:OCC) record revenue of AU$3 million for the September quarter, up 9.1% quarter over quarter, is consistent with <a href=\"https://laohu8.com/S/EZL.AU\">Euroz</a> Hartleys' fiscal 2026 revenue estimate of AU$14.4 million, according to a Thursday note from the investment advisory firm.</p><p>The first-quarter growth was due to higher sales of Remplir, the company's nerve repair product, in Australia and Singapore, Euroz Hartleys said.</p><p>Though Remplir did not have a material revenue contribution from the US market, Euroz Hartleys noted that the company expects US sales to start ramping up from the December quarter.</p><p>\"The US rollout of Remplir remains central to our investment thesis,\" the investment advisory firm added.</p><p>Euroz Hartleys maintained Orthocell's hold rating and raised its price target to AU$1.36 from AU$1.30.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orthocell's September Quarter Revenue Meets Fiscal 2026 Expectations, Euroz Hartleys Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrthocell's September Quarter Revenue Meets Fiscal 2026 Expectations, Euroz Hartleys Says\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-10-03 08:34</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Orthocell's (ASX:OCC) record revenue of AU$3 million for the September quarter, up 9.1% quarter over quarter, is consistent with <a href=\"https://laohu8.com/S/EZL.AU\">Euroz</a> Hartleys' fiscal 2026 revenue estimate of AU$14.4 million, according to a Thursday note from the investment advisory firm.</p><p>The first-quarter growth was due to higher sales of Remplir, the company's nerve repair product, in Australia and Singapore, Euroz Hartleys said.</p><p>Though Remplir did not have a material revenue contribution from the US market, Euroz Hartleys noted that the company expects US sales to start ramping up from the December quarter.</p><p>\"The US rollout of Remplir remains central to our investment thesis,\" the investment advisory firm added.</p><p>Euroz Hartleys maintained Orthocell's hold rating and raised its price target to AU$1.36 from AU$1.30.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2572631522","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2572631522","pubTimestamp":1759451674,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Orthocell's  record revenue of AU$3 million for the September quarter, up 9.1% quarter over quarter, is consistent with Euroz Hartleys' fiscal 2026 revenue estimate of AU$14.4 million, according to a Thursday note from the investment advisory firm.The first-quarter growth was due to higher sales of Remplir, the company's nerve repair product, in Australia and Singapore, Euroz Hartleys said.Though Remplir did not have a material revenue contribution from the US market, Euroz Hartleys noted that the company expects US sales to start ramping up from the December quarter.\"The US rollout of Remplir remains central to our investment thesis,\" the investment advisory firm added.Euroz Hartleys maintained Orthocell's hold rating and raised its price target to AU$1.36 from AU$1.30.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","OCC.AU":"ORTHOCELL LTD","BK7508":"医药生物股"},"translate_title":"Euroz Hartleys表示，Orthocell 9月份季度收入符合2026财年预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OCC.AU":1},"content_text":"Orthocell's (ASX:OCC) record revenue of AU$3 million for the September quarter, up 9.1% quarter over quarter, is consistent with Euroz Hartleys' fiscal 2026 revenue estimate of AU$14.4 million, according to a Thursday note from the investment advisory firm.The first-quarter growth was due to higher sales of Remplir, the company's nerve repair product, in Australia and Singapore, Euroz Hartleys said.Though Remplir did not have a material revenue contribution from the US market, Euroz Hartleys noted that the company expects US sales to start ramping up from the December quarter.\"The US rollout of Remplir remains central to our investment thesis,\" the investment advisory firm added.Euroz Hartleys maintained Orthocell's hold rating and raised its price target to AU$1.36 from AU$1.30.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}